- Augmenta Bioworks and TFF Pharmaceuticals Inc TFFP have announced positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody, AUG-3387, binds to and neutralizes the SARS-CoV-2 Delta variant (B.1.617.2).
- The companies have selected a final formulation of AUG-3387 that will be used to complete in vivo preclinical efficacy studies in the coming weeks and will proceed with toxicology studies by the end of 2021.
- Ongoing formulation development studies are expected to demonstrate that a sufficient dose of AUG-3387 to achieve a neutralizing concentration in the lungs can be delivered via already approved commercial dry powder inhaler devices.
- Price Action: TFFP shares are up 1.50% at $8.78 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
